RNXT
RenovoRx, Inc.
Biotechnology
Market Cap$32M
5Y Perf.-91.4%
Compare Stocks
2 / 10Try these comparisons:
Stock Comparison
RNXT vs CRIS
Revenue, margins, valuation, and 5-year total return — side by side.
CRIS
Curis, Inc.
Biotechnology
Market Cap$76M
5Y Perf.-99.7%
RNXT vs CRIS — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | RNXT | CRIS |
|---|---|---|
| Industry | Biotechnology | Biotechnology |
| Market Cap | $32M | $76M |
| Revenue (TTM) | $928K | $9M |
| Net Income (TTM) | $-11M | $-8M |
| Gross Margin | 67.8% | 99.5% |
| Operating Margin | -12.5% | -348.4% |
| Total Debt | $278K | $2M |
| Cash & Equiv. | $7M | $5M |
RNXT vs CRIS — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
RNXT
CRIS
| Stock | Aug 21 | May 26 | Return |
|---|---|---|---|
| RenovoRx, Inc. (RNXT) | 100 | 8.6 | -91.4% |
| Curis, Inc. (CRIS) | 100 | 0.3 | -99.7% |
Price return only. Dividends and distributions are not included.
Quick Verdict: RNXT vs CRIS
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: RNXT leads in 3 of 6 categories, making it the strongest pick for growth and revenue expansion and capital preservation and lower volatility. Curis, Inc. is the stronger pick specifically for profitability and margin quality and operational efficiency and capital deployment. As sector peers, any of these can serve as alternatives in the same allocation.
RNXT
RenovoRx, Inc.
The Income Pick
RNXT carries the broadest edge in this set and is the clearest fit for income & stability and long-term compounding.
- beta 1.18
- -87.9% 10Y total return vs CRIS's -99.7%
- Lower volatility, beta 1.18, Low D/E 6.2%, current ratio 4.10x
Best for: income & stability and long-term compounding
CRIS
Curis, Inc.
The Growth Play
CRIS is the clearest fit if your priority is growth exposure.
- Rev growth -13.4%, EPS growth 91.6%, 3Y rev CAGR -2.4%
- -80.3% margin vs RNXT's -12.0%
- -26.1% ROA vs RNXT's -99.1%
Best for: growth exposure
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | RNXT | 46.2% revenue growth vs CRIS's -13.4% |
| Quality / Margins | CRIS | -80.3% margin vs RNXT's -12.0% |
| Stability / Safety | RNXT | Beta 1.18 vs CRIS's 1.87, lower leverage |
| Dividends | Tie | Neither stock pays a meaningful dividend |
| Momentum (1Y) | RNXT | -17.0% vs CRIS's -72.0% |
| Efficiency (ROA) | CRIS | -26.1% ROA vs RNXT's -99.1% |
RNXT vs CRIS — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
FY 2024
FY 2025
RNXT vs CRIS — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLRNXTLAGGINGCRIS
CRISCuris, Inc.
1leads
RNXTRenovoRx, Inc.
4leads
6 Total Categories
CATEGORYLEADERvs CRISMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
CRIS5/5
Valuation MetricsMultiples, price ratios, and targets
RNXT2/3
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
RNXT5/7
Total Returns1Y, 3Y, 5Y total returns with dividends
RNXT6/6
Risk & VolatilityBeta, volatility, and downside exposure
RNXT2/2
Analyst OutlookRatings, price targets, and dividends
—
—
Income & Cash Flow (Last 12 Months)
CRIS leads this category, winning 5 of 5 comparable metrics.
Income & Cash Flow (Last 12 Months)
CRIS is the larger business by revenue, generating $9M annually — 10.2x RNXT's $928,000. Profitability is closely matched — net margins range from -80.3% (CRIS) to -12.0% (RNXT).
| Metric | RNXTRenovoRx, Inc. | CRISCuris, Inc. |
|---|---|---|
| RevenueTrailing 12 months | $928,000 | $9M |
| EBITDAEarnings before interest/tax | -$9M | -$33M |
| Net IncomeAfter-tax profit | -$11M | -$8M |
| Free Cash FlowCash after capex | -$10M | -$27M |
| Gross MarginGross profit ÷ Revenue | +67.8% | +99.5% |
| Operating MarginEBIT ÷ Revenue | -12.5% | -3.5% |
| Net MarginNet income ÷ Revenue | -12.0% | -80.3% |
| FCF MarginFCF ÷ Revenue | -11.2% | -2.9% |
| Rev. Growth (YoY)Latest quarter vs prior year | — | -66.0% |
| EPS Growth (YoY)Latest quarter vs prior year | +19.3% | +198.4% |
CRIS leads this category, winning 5 of 5 comparable metrics.
Valuation Metrics
RNXT leads this category, winning 2 of 3 comparable metrics.
Valuation Metrics
| Metric | RNXTRenovoRx, Inc. | CRISCuris, Inc. |
|---|---|---|
| Market CapShares × price | $32M | $76M |
| Enterprise ValueMkt cap + debt − cash | $25M | $73M |
| Trailing P/EPrice ÷ TTM EPS | -2.38x | -0.99x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | — | — |
| Price / SalesMarket cap ÷ Revenue | 750.13x | 8.04x |
| Price / BookPrice ÷ Book value/share | 4.64x | 13.91x |
| Price / FCFMarket cap ÷ FCF | — | — |
RNXT leads this category, winning 2 of 3 comparable metrics.
Profitability & Efficiency
RNXT leads this category, winning 5 of 7 comparable metrics.
Profitability & Efficiency
RNXT delivers a -137.5% return on equity — every $100 of shareholder capital generates $-137 in annual profit, vs $-139 for CRIS. RNXT carries lower financial leverage with a 0.06x debt-to-equity ratio, signaling a more conservative balance sheet compared to CRIS's 0.30x. On the Piotroski fundamental quality scale (0–9), RNXT scores 5/9 vs CRIS's 3/9, reflecting solid financial health.
| Metric | RNXTRenovoRx, Inc. | CRISCuris, Inc. |
|---|---|---|
| ROE (TTM)Return on equity | -137.5% | -138.8% |
| ROA (TTM)Return on assets | -99.1% | -26.1% |
| ROICReturn on invested capital | — | — |
| ROCEReturn on capital employed | -3.4% | -2.3% |
| Piotroski ScoreFundamental quality 0–9 | 5 | 3 |
| Debt / EquityFinancial leverage | 0.06x | 0.30x |
| Net DebtTotal debt minus cash | -$7M | -$3M |
| Cash & Equiv.Liquid assets | $7M | $5M |
| Total DebtShort + long-term debt | $278,000 | $2M |
| Interest CoverageEBIT ÷ Interest expense | — | -107.35x |
RNXT leads this category, winning 5 of 7 comparable metrics.
Total Returns (Dividends Reinvested)
RNXT leads this category, winning 6 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in RNXT five years ago would be worth $1,212 today (with dividends reinvested), compared to $28 for CRIS. Over the past 12 months, RNXT leads with a -17.0% total return vs CRIS's -72.0%. The 3-year compound annual growth rate (CAGR) favors RNXT at -31.8% vs CRIS's -67.0% — a key indicator of consistent wealth creation.
| Metric | RNXTRenovoRx, Inc. | CRISCuris, Inc. |
|---|---|---|
| YTD ReturnYear-to-date | +5.4% | -41.1% |
| 1-Year ReturnPast 12 months | -17.0% | -72.0% |
| 3-Year ReturnCumulative with dividends | -68.2% | -96.4% |
| 5-Year ReturnCumulative with dividends | -87.9% | -99.7% |
| 10-Year ReturnCumulative with dividends | -87.9% | -99.7% |
| CAGR (3Y)Annualised 3-year return | -31.8% | -67.0% |
RNXT leads this category, winning 6 of 6 comparable metrics.
Risk & Volatility
RNXT leads this category, winning 2 of 2 comparable metrics.
Risk & Volatility
RNXT is the less volatile stock with a 1.18 beta — it tends to amplify market swings less than CRIS's 1.87 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. RNXT currently trades 60.7% from its 52-week high vs CRIS's 18.4% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | RNXTRenovoRx, Inc. | CRISCuris, Inc. |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.17x | 1.92x |
| 52-Week HighHighest price in past year | $1.45 | $3.13 |
| 52-Week LowLowest price in past year | $0.70 | $0.49 |
| % of 52W HighCurrent price vs 52-week peak | +60.7% | +18.4% |
| RSI (14)Momentum oscillator 0–100 | 45.0 | 48.9 |
| Avg Volume (50D)Average daily shares traded | 379K | 444K |
RNXT leads this category, winning 2 of 2 comparable metrics.
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
| Metric | RNXTRenovoRx, Inc. | CRISCuris, Inc. |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | — | — |
| Price TargetConsensus 12-month target | — | — |
| # AnalystsCovering analysts | — | — |
| Dividend YieldAnnual dividend ÷ price | — | — |
| Dividend StreakConsecutive years of raises | — | — |
| Dividend / ShareAnnual DPS | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% |
Insufficient data to determine a leader in this category.
Key Takeaway
RNXT leads in 4 of 6 categories (Valuation Metrics, Profitability & Efficiency). CRIS leads in 1 (Income & Cash Flow).
Best OverallRenovoRx, Inc. (RNXT)Leads 4 of 6 categories
Loading custom metrics...
RNXT vs CRIS: Frequently Asked Questions
7 questions · data-driven answers · updated daily
01Which is the better long-term investment — RNXT or CRIS?
Over the past 5 years, RenovoRx, Inc.
(RNXT) delivered a total return of -87. 9%, compared to -99. 7% for Curis, Inc. (CRIS). Over 10 years, the gap is even starker: RNXT returned -88. 1% versus CRIS's -99. 7%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
02Which is safer — RNXT or CRIS?
By beta (market sensitivity over 5 years), RenovoRx, Inc.
(RNXT) is the lower-risk stock at 1. 17β versus Curis, Inc. 's 1. 92β — meaning CRIS is approximately 64% more volatile than RNXT relative to the S&P 500. On balance sheet safety, RenovoRx, Inc. (RNXT) carries a lower debt/equity ratio of 6% versus 30% for Curis, Inc. — giving it more financial flexibility in a downturn.
03Which is growing faster — RNXT or CRIS?
On earnings-per-share growth, the picture is similar: Curis, Inc.
grew EPS 91. 6% year-over-year, compared to 26. 0% for RenovoRx, Inc.. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
04Which has better profit margins — RNXT or CRIS?
Curis, Inc.
(CRIS) is the more profitable company, earning -80. 3% net margin versus -205. 0% for RenovoRx, Inc. — meaning it keeps -80. 3% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: CRIS leads at -348. 4% versus -255. 1% for RNXT. At the gross margin level — before operating expenses — RNXT leads at 100. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
05Which pays a better dividend — RNXT or CRIS?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
06Is RNXT or CRIS better for a retirement portfolio?
For long-horizon retirement investors, RenovoRx, Inc.
(RNXT) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 1. 17)). Curis, Inc. (CRIS) carries a higher beta of 1. 92 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (RNXT: -88. 1%, CRIS: -99. 7%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
07What are the main differences between RNXT and CRIS?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.